Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
批准号:
10646303
负责人:
Robert McCullough Anthony
金额:
$82.3万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-07-01 至 2025-06-30
关键词:
Anti-Inflammatory AgentsAntibodiesAntibody TherapyAutoantigensAutoimmune DiseasesB-LymphocytesBindingBiologicalBiological AssayBiologyBiophysicsBlocking AntibodiesCD4 Positive T LymphocytesCell-Mediated CytolysisCellsClinicalCommunicable DiseasesComplement 1qComplement-Dependent CytotoxicityComplexDataDevelopmentDiseaseDoseEffector CellFamilyGalectin 3GlycoengineeringGoalsHumanHypersensitivityIgG ReceptorsIgG1IgG2IgG3IgG4Immune checkpoint inhibitorImmunoglobulin GImmunologyImmunotherapeutic agentIn VitroInflammationInflammatoryIntravenous ImmunoglobulinsKnowledgeLamininLesionMS4A1 geneMalignant NeoplasmsMediatingMissionMusPathologyPatientsPhagocytosisPlasma CellsPolysaccharidesPost-Translational Protein ProcessingPublic HealthRecombinant Immune GlobulinRegulationResearchResolutionRoleSignal TransductionTestingTherapeutic UsesTherapeutic antibodiesTransplantationUnited States National Institutes of Healthanti-CD20antibody-dependent cell cytotoxicityautoinflammatory diseasescytotoxicdefined contributiondesignempowermentexperimental studygain of functionglycosylationimmunoregulationin vivoinnovationinsightneoplasm immunotherapyprogrammed cell death protein 1receptorreceptor bindingsialylationstandard of caresuccesstranslational impact
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract.
IgG4-related diseases (IgG4-RDs) are a family of related autoinflammatory diseases characterized by fibrotic
lesions comprised of CD4+ T cells and IgG4+ plasma cells, and markedly elevated oligoclonal IgG4. However,
whether IgG4 antibodies contribute to IgG4-RD pathology remains unclear. Despite the tremendous clinical
success of immunotheraputics, little is known regarding IgG4 biology relative to IgG1. Our long-term goals are
to understand the role and regulation of glycosylation to antibody biology, to ultimately modulate antibody effector
functions in vitro and in vivo. The overall objective of this application is to comprehensively dissect cytotoxic
activity of sialylated IgG4. Our central hypothesis is autoantigen-specific IgG4 in IgG4-RD is sialylated, and
contributes to the pathology Of IgG4-RD. Our approach combines characterizing IgG from the sera of IgG4-RD
and healthy patients, while examining precisely glycoengineered IgG4 in receptor binding and effector function
assays.
Our hypothesis is informed by preliminary data shown here in the Approach subsection of the Research Strategy
section. The rationale that underlies the proposed research is understanding how IgG4 mediate cytotoxic effector
function will enable new insights into IgG biology, and may lead to development of innovative antibody-based
therapies. We will test our central hypothesis and, thereby, attain the objective of this application by pursuing the
following three specific aims using a combination of biophysical experiments, and in vitro and in vivo functional
assays.
1) Define the glycosylation and FcγRs-binding profiles of total and autoantigen-specific IgG in IgG4-RD.
Hypothesis: Sialylation enables FcγR binding by IgG4.
2) Examine the effector functions of sialylated IgG4 in vitro. Hypothesis: Sialylated IgG4 mediates effector
cell-specific pro-inflammatory effector functions.
3) Determine the in vivo effector functions of sialylated IgG4. Hypothesis: Sialylated IgG4 exerts pro-
inflammatory effector functions in vivo.
This proposal is expected to have broad clinical implications, ranging from diseases where elevated IgG4 titers
are associated in the pathology or resolution, as well as to design of immunotherapeutics, and represents a
substantive departure from the status quo by underscoring the cytotoxic capacity of IgG4.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.
基于嵌合血凝素的流感病毒疫苗接种在人体中引发的抗体赋予 FcγR 依赖性体内保护。
DOI:
10.1073/pnas.2314905120
发表时间:
2023
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[Edgar,JuliaE, Trezise,Stephanie, Anthony,RobertM, Krammer,Florian, Palese,Peter, Ravetch,JeffreyV, Bournazos,Stylianos]
通讯作者:
Bournazos,Stylianos
Harnessing the anti-inflammatory activity of extracellular sialylation of IgG.
-
批准号:10394191
-
项目类别:
-
资助金额:$54.97万
-
财政年份:2021
-
负责人:Robert McCullough Anthony
-
依托单位:
Harnessing the anti-inflammatory activity of extracellular sialylation of IgG.
-
批准号:10096946
-
项目类别:
-
资助金额:$56.67万
-
财政年份:2021
-
负责人:Robert McCullough Anthony
-
依托单位:
Harnessing the anti-inflammatory activity of extracellular sialylation of IgG.
-
批准号:10589050
-
项目类别:
-
资助金额:$54.97万
-
财政年份:2021
-
负责人:Robert McCullough Anthony
-
依托单位:
Glycoengineering IgA1 in IgA nephropathy
-
批准号:10179319
-
项目类别:
-
资助金额:$25.08万
-
财政年份:2020
-
负责人:Robert McCullough Anthony
-
依托单位:
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
-
批准号:10202454
-
项目类别:
-
资助金额:$82.3万
-
财政年份:2020
-
负责人:Robert McCullough Anthony
-
依托单位:
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
-
批准号:10032974
-
项目类别:
-
资助金额:$84.0万
-
财政年份:2020
-
负责人:Robert McCullough Anthony
-
依托单位:
Novel Roles of IgE Glycosylation in Anaphylaxis
-
批准号:10312796
-
项目类别:
-
资助金额:$49.72万
-
财政年份:2019
-
负责人:Robert McCullough Anthony
-
依托单位:
Novel Roles of IgE Glycosylation in Anaphylaxis
-
批准号:10543147
-
项目类别:
-
资助金额:$49.72万
-
财政年份:2019
-
负责人:Robert McCullough Anthony
-
依托单位:
Novel Roles of IgE Glycosylation in Anaphylaxis
-
批准号:10084262
-
项目类别:
-
资助金额:$49.72万
-
财政年份:2019
-
负责人:Robert McCullough Anthony
-
依托单位:
Understanding the role of Epigenetic Reader SP140 in IBD
-
批准号:10242706
-
项目类别:
-
资助金额:$29.12万
-
财政年份:2018
-
负责人:Robert McCullough Anthony
-
依托单位:
The importance of the IgG4 glycome in IgG4-related disease(s)
-
批准号:8732924
-
项目类别:
-
资助金额:$16.8万
-
财政年份:2014
-
负责人:Robert McCullough Anthony
-
依托单位:
Glycoengineering In Vivo
-
批准号:8757047
-
项目类别:
-
资助金额:$261.0万
-
财政年份:2014
-
负责人:Robert McCullough Anthony
-
依托单位:
SIGN receptors and the antiinflammatory activity of sialylated IgG Fcs
-
批准号:8526358
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2012
-
负责人:Robert McCullough Anthony
-
依托单位:
SIGN receptors and the antiinflammatory activity of sialylated IgG Fcs
-
批准号:8029405
-
项目类别:
-
资助金额:$16.2万
-
财政年份:2012
-
负责人:Robert McCullough Anthony
-
依托单位:
The importance of the IgG4 glycome in IgG4-related disease(s)
-
批准号:8840539
-
项目类别:
-
资助金额:$15.6万
-
财政年份:--
-
负责人:Robert McCullough Anthony
-
依托单位:
海外基金